Fourth-generation accommodating IOL gets FDA ok

Article

The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market.

The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market. The newest generation of the Crystalens provides an increased depth of focus without creating any additional dysphotopsia, thereby enhancing the near vision and maintaining the intermediate and distance vision improvement offered by the third-generation lens.

John Hovanesian, MD, FACS of the Jules Stein Eye Institute, UCLA, California, US and colleagues implanted the lens, using the same surgical protocol as with previous versions of the Crystalens, into eyes (n=125) with visually significant cataract combined with astigmatism of

Bausch & Lomb has now begun shipping of the fourth-generation Crystalens HD.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.